CDDF
Cancer Drug Development Forum

ANNUAL REPORT

2023

CANCER DRUG DEVELOPMENT FORUM (CDDF)

www.cddf.org
info@cddf.org

Table of **Contents**

Cancer Drug Development Forum (CDDF)

The Year in Review

Dear CDDF community,

As we reflect on the past year, we find ourselves in a landscape fraught with complex political, economic, and environmental issues further complicated by the aftermath of the COVID-19 pandemic and conflicts in Ukraine and the Middle East.

These adverse conditions have impacted so many, including cancer patients and those in the oncology community. Despite this challenging backdrop, the CDDF continued to foster timely discussions on relevant topics throughout 2023, demonstrating resilience and proficiency in its mission to advance cancer drug development.

The CDDF's activities focused on two main areas of development in 2023: **innovations and advancements** and **EU policy and legislation**.

Our multi-stakeholder discussions addressed diverse challenges in advancing cancer treatments, including regulatory issues in combining immuno-oncology with radiotherapy, hurdles in cancer prevention treatments, diversity in clinical data, decentralised clinical trials, optimising drug doses, innovating oncology trial designs, and integrating biomarkers in precision oncology.

In addition, live webinars offered essential presentations and discussions on the European Commission's "Europe's Beating Cancer Plan", the impact of the delayed implementation of the In Vitro Diagnostic Regulation on tens of thousands of patients, and the status of the new Health Technology Assessment regulation aiming to improve EU patients' equal access to novel anti-cancer agents.

The CDDF continued to expand its reach within the oncology community over the past year. In September, we partnered with Accelerating Anti-cancer Agent Development and Validation (AAADV) and the American Society of Clinical Oncology (ASCO) for a workshop emphasising the potential and opportunities for proven and novel cancer prevention strategies. In addition, our engagement with US and other regulatory bodies to address and prioritise global regulatory frameworks is ongoing.

The CDDF published two white papers and one article in 2023 to amplify the influence of CDDF-generated discussions:

- **Empowering involvement and engagement of patients with cancer in oncology drug development**
- **Histology independent drug development – is this the future for cancer drugs?**
- **Pragmatic solutions for optimizing oncology drug development trials**

These documents advocate for optimal strategies for delivering cancer treatments and help raise the profile of cancer drug development issues.

Cancer Drug Development Forum (CDDF)

The Year in Review

Aiming for a balance of perspectives, the CDDF continues to increase the scope and range of its stakeholders. In 2023, we added three new small and medium-sized industry members, and CDDF discussions now feature increased participation from regulatory agencies, academia, and patient advocacy groups. We continue to develop robust collaborative relationships with these groups and other oncology associations.

The CDDF is committed to upholding a dynamic and diverse composition of board members, ensuring sound and efficient governance practices. To this end, we were delighted to welcome three new board members in 2023 with a wealth of expertise and experience in clinical and regulatory settings: Dr Christian Schneider, Dr Fergus Sweeney and Dr Rosa Giuliani.

We have much to be optimistic about as we look ahead to 2024. Our program of events and widening network will ensure another year of growth and innovation towards advancing cancer care. The CDDF platform will be at the forefront of timely discussions on topics affecting the future of cancer care, such as real-world evidence, decentralised care and trials, drug and biomarker combinations, clinical research in Central and Eastern Europe and innovation in rare cancers.

We will join forces with partners worldwide throughout the year. Notably, we are working towards broadening our engagement with EU audiences through collaborative initiatives. Scheduled events include the joint European Society for Medical Oncology(ESMO)-CDDF session in September. Later that month, we will hold a workshop with the European Organisation for the Research and Treatment of Cancer (EORTC) to highlight innovation in treating rare cancers.

The CDDF is grateful to all who have contributed time and expertise to help achieve successful outcomes in 2023 - thank you for your steadfast support and commitment to our shared mission, which we will continue to advance together in 2024.

Yours sincerely,

Prof. Ruth Plummer
Chairperson of the CDDF Board of Director

ABOUT
THE CDDF

WHAT IS THE CDDF?

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in Belgium that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in cancer drug development.

CDDF'S MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to **increase efficiency** in cancer drug development and **accelerate the delivery of effective oncology treatment to patients**.

HOW DOES THE CDDF ADVANCE ITS MISSION?

To accomplish its mission, the CDDF offers workshops, conferences and webinars that bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups. By providing a non-competitive, non-commercial platform for multi-stakeholder discussions and collaboration, the CDDF stimulates advancement and innovation in the field through scientific debate and open discussion.

ORGANISATIONAL **STRUCTURE**

CDDF MEMBERS OF THE GENERAL ASSEMBLY

CDDF BOARD OF DIRECTORS

Ruth Plummer
Chairperson

Eva Skovlund
Vice-Chairperson

Axel Glasmacher
Treasurer

Jaap Verweij
Managing Director

Catarina Edfjäll
Board member

Rosa Giuliani
Board member

Mark Lawler
Board member

Christian Schneider
Board member

Fergus Sweeney
Board member

Stefan Symeonides
Board member

CDDF OFFICE - BRUSSELS

Jaap Verweij
Managing Director

Marjorie Recorbet
Director of Operations

Giorgia Campagnano
Event Manager

Caroline Marissal
Event Coordinator

Hyunmin Park
Communication/Community Coordinator

LEADERSHIP

GOVERNANCE

CDDF Board of Directors

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs. These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, regulatory scientists and a statistician representing a range of perspectives within the drug development process. The directors are elected for a period of three years.

Full and Honorary Members of Association

Full and honorary Members of the CDDF are committed to accelerating oncology drug development and delivering optimal treatment to cancer patients. Members have the right to attend General Assembly meetings, which take place once a year and are the association's sovereign authority. At these meetings, Members monitor, assess and guide CDDF's work programme, organisational directions and best practices.

16
Full/honorary Members of the association

10
CDDF Board of Directors

4
CDDF office staff members

LEADERSHIP

CDDF BOARD OF DIRECTORS

PROF. JAAP VERWEIJ
Managing Director

PROF. RUTH PLUMMER
Chairperson

PROF. EVA SKOVLUND
Vice-Chairperson

PROF. AXEL GLASMACHER
Treasurer

DR. CATARINA EDFJALL
Board Member

PROF. MARK LAWLER
Board Member

PROF. STEFAN SYMEONIDES
Board Member

DR. ROSA GIULIANI
Board Member

DR. FERGUS SWEENEY
Board Member

DR. CHRISTIAN SCHNEIDER
Board Member

TOGETHER, WE IDENTIFY AND OVERCOME CHALLENGES IN THE **DEVELOPMENT** AND **DELIVERY** OF **CANCER DRUGS**

LEADERSHIP

CHANGES IN BOARD COMPOSITION

In accordance with the CDDF Articles of Association, a Member of the CDDF Board of Directors is appointed for a period of three years. The mandate of the member is renewable. This rotation policy serves to develop robust governance practices within the CDDF and encourages a dynamic and diverse composition of the Board of Directors.

At the CDDF's General Assemblies in May and December 2023, the following changes were approved:

- **Dr. Katrin Rupalla** resigned from her position as a member of the CDDF Board of Directors, effective May 22, 2023.
- **Prof. Ruth Plummer** was re-appointed as a member of the CDDF Board of Directors and re-elected as Chairperson for a three-year term.
- **Prof. Eva Skovlund** was re-appointed as a member of the CDDF Board of Directors and re-elected as Vice Chairperson for a three-year term.
- **Dr. Catarina Edfjäll** was re-appointed as a member of the CDDF Board of Directors for a three-year term.
- **Dr. Rosa Giuliani**, **Dr. Christian Schneider** and **Dr. Fergus Sweeney** were newly appointed as board members in December 2023 for a three-year term.

CONFLICTS OF INTEREST

In accordance with the Articles of Association, Board members have declared any potential conflicts of interest. The disclosure forms are provided in the appendix (page 30).

CDDF **OFFICE**

OFFICE STAFF MEMBERS



EMPLOYMENT DETAILS

- **Jaap Verweij, Managing Director**
  Consultancy contract renewed until 30 September 2025
- **Marjorie Recorbet, Director of Operations**
  2.5 days/week contract
- **Giorgia Campagnano**
  4 days/week contract
- **Caroline Marissal**
  4 days/week contract
- **Hyunmin Park**
  3 day/week contract

FINANCIAL STATEMENT

REVENUE AND EXPENSES IN THE 2023 FISCAL YEAR

Total Revenue
€ 691,117.99

Total Expenses
€ 658,195.52

Balance
€ 32,922.47

TOTAL REVENUE 2023



Total Revenue
€ 691,117.99

- Membership fees
- Income from events
- Other income (tax)

FINANCIAL STATEMENT

TOTAL EXPENSES 2023

Total Expenses

€ 658,195.52

- Human resources
- Accounting and tax management
- Office & IT costs
- Board of Directors
- Legal costs
- Event organization
- Miscellaneous expenses & depreciation



ACHIEVEMENTS

OVERVIEW OF ACTIVITIES

Throughout 2023, the CDDF fostered a more inclusive and balanced dialogue by actively engaging a wider range of stakeholders from regulatory bodies, academia, and patient advocacy groups. The CDDF's hybrid meetings and webinars effectively addressed the two key areas of focus for the year: advancements and innovations in oncology drug development and the evolving regulatory landscape and policies within the European Union.

CDDF MEETINGS IN 2023

ANNUAL CONFERENCE

Challenges in Clinical Trial Performance

6 – 8 February 2023
Hybrid, NL

MULTI-STAKEHOLDER WORKSHOP

Dose Optimisation in Early Oncology Drug Development

3 – 4 April 2023
Hybrid, NL

MULTI-STAKEHOLDER WORKSHOP

Innovative Oncology Trial Designs

18 – 19 September 2023
Hybrid, NL

MULTI-STAKEHOLDER WORKSHOP

The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology

13 – 14 November 2023
Hybrid, NL

ACHIEVEMENTS

OVERVIEW OF ACTIVITIES

CDDF JOINT MEETING

AAADV-ASCO-CDDF WORKSHOP

Global Cancer Drug Development

12 – 15 September 2023
Online

CDDF LIVE WEBINAR SERIES

Immunotherapy and Radiotherapy Combinations
Part 2: Regulatory Considerations

27 February 2023

Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception

15 June 2023

Beating Cancer In Europe - Time to Deliver

10 July 2023

Critical Impacts of the In Vitro Diagnostic Regulation (IVDR) Implementation on Patient Access to Clinical Trials

7 September 2023

Perspectives on the new EU Health Technology Assessment (HTA) Regulation 2021/2282

28 September 2023

ACHIEVEMENTS

OVERVIEW OF ACTIVITIES

Total number of CDDF meetings in 2023	4
Total number of CDDF webinars in 2023	5
Total number of participants	1118
Participant overall satisfaction rate	4.6/5

Number of Participants per Meeting/Webinar



ACHIEVEMENTS

Categories of Onsite Meeting Participants



This graph reflects categories of onsite meeting participants in 2023 excluding CDDF staff members and N/A

Countries of Meeting Participants (onsite & online)



TOP 5 COUNTRIES IN EUROPE

- United Kingdom (22%)
- Switzerland (21%)
- Germany (12%)
- Netherlands (10%)
- Belgium (8%)


elpia
DIA
Duke

ACHIEVEMENTS

CDDF MEETINGS IN 2023

Annual Conference: Challenges in Clinical Trial Performance

6-8 February 2023, hybrid, Noordwijk (NL)

The Annual Conference 2023 explored key aspects impacting the future performance of clinical trials aiming at drug registration. The program focused on challenges surrounding population diversity, practical considerations for decentralized trials, early-career obstacles faced by those involved in clinical trials, and evolving regulatory landscapes. This interactive meeting fostered insightful discussions, generating valuable takeaways and a comprehensive meeting report.

Multi-Stakeholder Workshop: Dose Optimization in Early Oncology Drug Development

3 – 4 April 2023, hybrid, Amsterdam (NL)

The CDDF held a multi-stakeholder workshop to discuss how dose optimization in the future could be implemented in early drug development based on new methodologies, considering the various views of all relevant stakeholders. The program centered on challenges in dose optimization, Project Optimus and other regulatory initiatives, methodological approaches, and potential approaches to move forward in this field. Key takeaways from this workshop are available in its executive summary.

ACHIEVEMENTS

CDDF MEETINGS IN 2023

Multi-Stakeholder Workshop: Innovative Oncology Trial Designs

18-19 September 2023, hybrid, Amsterdam (NL)

This workshop brought together experts from regulatory agencies, industry, academia and patient groups to discuss how novel techniques could be best implemented in drug development-related trials. It covered a range of topics, from novel (and surrogate) endpoints, estimands, patient-reported outcomes and harnessing real-world data, to novel statistical designs and methods. Take-home messages from this interactive meeting are available in the executive summary.

Multi-Stakeholder Workshop: The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology

13-14 November 2023, hybrid, Amsterdam (NL)



The CDDF organized a multi-stakeholder meeting on the rapidly evolving field of biomarkers in precision oncology. The program explored and evaluated various challenges and opportunities surrounding biomarkers in oncology drug development and the trials designed to obtain marketing approval in selected populations. It also examined the cost of not using biomarkers and the impact of In Vitro Diagnostic Regulation (IVDR). Key takeaways from the discussion are available in its executive summary.

ACHIEVEMENTS

CDDF WEBINARS IN 2023

Live Webinar: Immunotherapy and Radiotherapy Combinations - Part 2: Regulatory Considerations

27 February 2023, online

Prof. Paz Vellanki (FDA) presented on the regulatory considerations for combining immunotherapy and radiotherapy in cancer treatment. Following the presentation, she engaged in a moderated Q&A session with Prof. Ruth Plummer (CDDF) and Dr. Ricky Sharma (Varian/Siemens Healthineers). This event was the second part of the CDDF's live webinar series on the topic and offered a full recording and key takeaways from the discussion.

Live Webinar: Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception

15 June 2023, online

The CDDF hosted a webinar featuring Dr. Brian Cholewa (National Cancer Institute), who offered expert insight into novel and targeted agents in precision cancer prevention and interception. The presentation highlighted cancer prevention strategies and current initiatives, followed by an informative Q&A session moderated by Jaap Verweij (CDDF) and Kim Lyerly (Duke University). This event provided a valuable learning opportunity for CDDF stakeholders. Webinar outputs are available on the CDDF website.

ACHIEVEMENTS

CDDF WEBINARS IN 2023

Live Webinar: Beating Cancer In Europe – Time to Deliver

10 July 2023, online

The CDDF hosted a webinar on Europe's Beating Cancer Plan with Dr. Alberto Costa (European Commission) who presented the plan's history, current status, and future. Following the talk, Prof. Mark Lawler (CDDF & Queen's University Belfast UK) gave an overview of the Lancet Oncology European Cancer Groundshot commission regarding its cancer research. With the Q&A discussion moderated by Teodora Kolarova (International Neuroendocrine Cancer Alliance), the live webinar emphasized the importance of collaboration in tackling cancer across the EU. Webinar outputs are available on the CDDF website.

Live Webinar: Critical Impacts of the In Vitro Diagnostic Regulation (IVDR) Implementation on Patient Access to Clinical Trials

7 September 2023, online



Ms. Audrey Wolf (EFPIA) presented the impacts of the IVDR implementation on patient access to clinical trials at the CDDF webinar. She provided findings from an EFPIA internal survey that show more than 100 clinical trials are being delayed in Europe because of the IVDR, with an expected 238 to 420 trials to be delayed over the next 3 years. The takeaways from her talk and a Q&A session moderated by Jaap Verweij (CDDF) and Ruth Plummer (CDDF & Newcastle University) are available on the CDDF website.

ACHIEVEMENTS

CDDF WEBINARS IN 2023

Live Webinar: Perspectives on the new EU Health Technology Assessment (HTA) Regulation 2021/2282

28 September 2023

In this CDDF webinar, Marcus Guardian (EUnetHTA) and Julie Spony (European Patients' Forum) discussed the perspectives of assessors and patients on practical aspects regarding the establishment of EU Regulation 2021/2282 on Health Technology Assessment. The talks and the subsequent Q&A session moderated by Axel Glasmacher (CDDF) enhanced CDDF stakeholders' understanding of the new regulation, offering valuable learning materials.

CDDF BREAKS DOWN SILOS IN THE ONCOLOGY COMMUNITY AND FACILIATES OPEN, MEANINGFUL DIALOGUE AMONG ALL STAKEHOLDERS

CDDF
Cancer Drug Development Forum

> CDDF MEETINGS BRING TOGETHER REGULATORS, HTAs, THE INDUSTRY, ACADEMICS AND PATIENT ADVOCATES TO COLLABORATE

INCLUSIVE & COLLABORATIVE NETWORK OF MULTI-STAKEHOLDERS INVOLVED IN ONCOLOGY DRUG DEVELOPMENT

ACHIEVEMENTS

COLLABORATION

Recognizing collaboration as fundamental to its mission, the CDDF fostered and maintained close partnerships with diverse organizations representing key stakeholder perspectives in cancer drug development.

AAADV

The CDDF continued its active collaboration with the Accelerating Anticancer Agent Development and Validation (AAADV), exchanging best practices and information on cancer drug development.

In September 2023, the AAADV, ASCO and CDDF held a joint online workshop on global cancer drug development with special focus on the potential and opportunities for proven and novel cancer prevention strategies. Prof. Jaap Verweij (CDDF, NL) took part in its program committee to provide scientific inputs and guidance.

EFPIA

The CDDF maintained an ongoing dialogue with the European Federation of Pharmaceutical Industries and Associations (EFPIA) to identify key topics and potential speakers in the field of oncology drug development.

EORTC

The European Organisation for Research and Treatment of Cancer (EORTC) and CDDF strengthened their existing collaboration by jointly planning and developing a workshop on rare cancers planned for the coming year. This initiative reflects their shared commitment to fostering open dialogue and facilitating innovations in the community of cancer research.

ACHIEVEMENTS

COLLABORATION

EMA & FDA

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) continued their support for CDDF multi-stakeholder discussions in 2023. Both agencies provided valuable regulatory perspective on diverse topics in cancer drug development and took part in constructive discussions with the CDDF multi-stakeholder community.

ESMO

The CDDF revitalized its collaboration with the European Society for Medical Oncology (ESMO) by launching discussions and jointly developing an educational session on regulatory challenges in clinical cancer drug development that will take place in 2024.

WECAN

The Workgroup of European Cancer Patient Advocacy Networks (WECAN) and the CDDF made joint efforts to continuously push for the shared mission to improve cancer treatment. The WECAN and its representatives have served in various roles at CDDF meetings, helping the CDDF to better incorporate the patient perspective into multi-stakeholder discussions.

ACKNOWLEDGEMENT OF **SUPPORTERS**

The CDDF thanks its members and collaborators for their engagement and invaluable contribution to support the CDDF's mission in 2023.

CDDF INDUSTRY MEMBERS IN 2023

ACKNOWLEDGEMENT OF **SUPPORTERS**

COLLABORATORS IN 2023

AADV
Accelerating Anticancer Agent Development and Validation

efpia

EORTC
The future of cancer therapy

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

FDA U.S. FOOD & DRUG ADMINISTRATION

WECAN
Workgroup of European Cancer Patient Advocacy Networks



CDDF IN 2024:
A LOOK AHEAD



Key Discussion Topics in Cancer Drug Development

In 2024, the CDDF remains at the forefront, facilitating critical discussions on pressing topics shaping the future of cancer care. We will expand our reach even further, connecting with a broader range of stakeholders throughout Europe, especially in Central and Eastern regions, and aiming for global impact.

We will also strengthen collaborations with our partners to expedite the development and delivery of innovative cancer treatments to patients across Europe.

LIVE WEBINARS

- **Bayesian Statistics in Cancer Drug Development**
- **Cancer Medicines Forum**
- **EU Clinical Trials Regulation**
- **Big data and AI**
- **Follow-up webinar on EU HTA regulation**

CDDF IN 2024:
A LOOK AHEAD

MULTI-STAKEHOLDER MEETINGS

Focus of Discussion

1. Real-World Evidence
2. Reflections on CDDF Meetings in 2023
3. Decentralized Care and Trials
4. Impact of Recent Regulatory Changes
5. Drug & Biomarker Combination

Focus of Discussion

1. Current Status of Clinical Trials in CEE
2. Improving Clinical Trials in CEE
3. Clinical Trials in CEE: Industry Perspective
4. Innovative Concepts in CEE
5. Clinical Trials in CEE: Regulatory Perspective
6. Next Steps

CDDF IN 2024:
A LOOK AHEAD

MULTI-STAKEHOLDER MEETINGS

Focus of Discussion

1. **Challenges, Collaboration & Needs**
2. **Innovative Trial Designs**
3. **Innovative Solutions to Improve Access**
4. **Wrap-up & Next Steps**

CDDF-ESMO JOINT SESSION

Focus of Discussion

1. **Specifics of CHMP Assessment of Cancer Drugs**
   Aaron E. Sosa Mejia (Danish Medicines Agency)
2. **Current Status and Implications of the In Vitro Diagnostics Regulation (IVDR)**
   Audrey Wolf (EFPIA)
3. **Initiatives for a Joint EU HTA Assessment**
   Marcus Guardian (Dierks+Company)
4. **Q&A and Discussion**

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Ruth Plummer

Commercial organizations with actual/potential/perceived conflicts of interest of a financial/functional/any other nature

- Honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa, BenevolentAI and Sanofi Aventis.
- Honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo, SOTIO, Biotech AG, and AstraZeneca
- Payment for the delivery of educational talks or chairing educational meetings from AstraZeneca, Novartis, Bayer, MSD and BMS.

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 22 January 2024

Prof. Eva Skovlund

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 22 January 2024

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Jaap Verweij

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- IDRX
- Deuter Oncology
- Boehringer Ingelheim

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 23 January 2024

Prof. Axel Glasmacher

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of Board of Directors (Current)
  - Active Biotech AB
  - Ryvu Pharmaceuticals
- Consultancy (2022-2024)
  - Active Biotech AB
  - Nanexa AB
  - Cellex GmbH
  - Ryvu Therapeutics S.A.
  - Oncopeptides AB
  - Excerpta Medica BV

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 23 January 2024

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Catarina Edfjäll

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 5 February 2024

Prof. Mark Lawler

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Honoraria from Bayer, Carnall Farrar, EMD Serono, Novartis, Pfizer and Roche

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 28 March 2023

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Rosa Giuliani

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 3 February 2024

Dr. Christian Schneider

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Working as a consultant with multiple pharmaceutical companies across all products and indications in the biopharmaceutical space.
- Salary from Cencora without any direct interest in any company

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 4 February 2024

Dr. Fergus Sweeney

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of WHO Technical Advisory Group on Development of Guidance on Best Practices for Clinical Trials

Last updated on 22 January 2024

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- No financial interests in any commercial pharmaceutical entity
- No personal gain from any of the below unless highlighted in bold
  - Educational & travel:
    - Ipsen (6/17, 6/18, 9/19, 9/21, 9/22), EUSA (6/21, 6/22), BioNTech (11/21), MSD (2/22)
  - Consultancy (my institution):
    - Nil current
  - Scientific advisory role (my institution, unless highlighted in **bold**):
    - Duke Street Bio (22/3/22 –)
    - Eisai (18/3/19, 20/12/22)
    - **Ellipses** (11/4/18 –)
    - Eugit Therapeutics (10/22 -)
    - **Exscientia** (13/8/23 -)
    - Grey Wolf Therapeutics (25/5/23 –)
    - MSD (10/5/19, 3/7/20, 4/3/21, 6/7/21, 7/7/21, 15/10/21, 17/3/22, 15/12/22)
  - Speaker (my institution, unless highlighted in **bold**):
    - Eisai (31/10/22)
    - **Ipsen** (26/10/21 clinicians; 6/11/21, 18/3/22, 30/3/23 & 21/9/23 non-promotional educational, unrelated to company's products)
    - MSD (31/3/22 internal MSD, 23/5/22 internal MSD)
  - Research funding (my institution):
    - MSD (trial funding and drug supply, trials staff) (6/15-)
    - Verastem (trial funding and drug supply) (6/15-)
  - Independent Data / Safety Monitoring (my institution, unless highlighted in **bold**):
    - **Exscientia** (13/8/23 -)
    - **WCG** (16/2/23 –)
    - Grey Wolf Therapeutics (25/5/23 –)

Continued on the next page

APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- No personal gain from any of the below unless highlighted in bold
  - Research collaboration (as PI/CI):
    - Pharmaceutical companies
      - MSD (MK3475-564 13/2/17, MK3475-U03a/b), BioNTech (5/11/19), Boston Pharmaceuticals (2/11/17 – 12/4/21), Sierra Oncology (SRA737-01, 12/4/17-12/19), Agalimmune/BioLineRx (1/5/19), Nucana (13/3/19), Nouscom (26/4/21), Sapience (18/3/20), Roche (14/6/21), Incyte (26/10/21), Scancell (ModiFY 22/4/22), Medannex (4/8/23). In set-up: AZ, Grey Wolf Therapeutics, Nuvectis, Salubris Bio, Seagen, TargImmune
      - Co-I
        - MSD (MK3475-427, 005), Anicca, ARCADIAN, Ipsen (CaboPoint 18/2/21), CALYPSO, CAPER, CAReS, CellCentric (9/12/20), Eisai (CLEAR 20/6/17), LY314, MITRE, NAXIVA, PRISM, RAMPART, A-PREDICT, STAR, TARGET, IMAGINE
      - CROs
        - TMC Pharma, Chiltern, Clinipace, Precision for Medicine, ICON, PharmOlam

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- University of Edinburgh – Senior Clinical Lecturer in Experimental Cancer Medicine
  - 24 funded hours per week
- NHS – Consultant Medical Oncologist (Edinburgh Cancer Centre)
  - 4 funded hours per week (as South East Scotland Cancer Research Network Lead); additional on-call and unfunded work (including renal cancer, registrar teaching, clinical care of trials patients)
- CRUK – Medical Advisor (Centre for Drug Development)
  - 20 funded hours per week
- Collaborating universities (directly linked by research funding/trial funding)
  - University of Glasgow (inc Glasgow CRUK CTU), University of Southampton, University of Leicester, Queens University Belfast, Institute of Cancer Research London

Last updated on 22 February 2024

Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels.
Enterprise number: 738.523.752

info@cddf.org

www.cddf.org

@cddf_eu

The Cancer Drug Development Forum (CDDF)